Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of $0.01, $0.50 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $149.41 million versus the consensus estimate of $156.83 million.

GUIDANCE:

Blueprint Medicines sees FY2025 revenue of $700-720 million, versus the consensus of $723.2 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.